Kolon Life Science’s ‘Invossa-K’ becomes game changer in osteoarthritis market
After being officially launched on 6 November, Kolon Life Science’s(CEO Woo-Seok Lee) ‘Invossa-K Inj’ has been settled as a new ‘game changer’ through various market activities, such as attracting foreign patients from the Korean osteoarthritis treatment market, taking more than 100th procedures ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
